Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?Zacks Investment Research • 01/01/24
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a BetZacks Investment Research • 12/15/23
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 12/12/23
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs)GlobeNewsWire • 12/12/23
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple MyelomaGlobeNewsWire • 11/28/23
Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom FishingZacks Investment Research • 11/13/23
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/01/23
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC™ Degrader in Development for Multiple MyelomGlobeNewsWire • 10/11/23
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/08/23
C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/08/23
C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 07/15/23
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC™ Degrader Targeting EGFR L858R for Non-Small Cell Lung CancerGlobeNewsWire • 07/05/23
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLCGlobeNewsWire • 05/30/23
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/04/23
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/04/23
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysGlobeNewsWire • 04/19/23
Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)Zacks Investment Research • 04/11/23